What Sionna Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 2 | 86 |
| Total trades | 10 | 97 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 468,852 | 499,602 |
| Disposed | 3,448,811 | 6,428,838 |
| Net activity | −2,979,959 | −5,929,236 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Ridloff Elena | CFO and CBO | Sep 17 | Grant / award · A | +47,268 | — | — | 133,069 |
| Ridloff Elena | CFO and CBO | Sep 17 | Grant / award · A | +47,269 | — | — | 85,801 |
| Fitzpatrick Jennifer | CLO and Head of Program Mgmt. | Sep 17 | Grant / award · A | +28,132 | — | — | 56,265 |
| Fitzpatrick Jennifer | CLO and Head of Program Mgmt. | Sep 17 | Grant / award · A | +28,133 | — | — | 28,133 |
| Ra Capital MANAGEMENT, L.p. | Director | Sep 17 | Open-market sale · S | −33,800 | $7.46 | −$252K | 3,448,812 |
| Ra Capital MANAGEMENT, L.p. | Director | Sep 17 | Open-market sale · S | −3,415,011 | $6.32 | −$21.6M | 3,482,612 |
| McKee Charlotte | CMO and Head of R&D | Sep 17 | Grant / award · A | +50,000 | — | — | 128,415 |
| McKee Charlotte | CMO and Head of R&D | Sep 17 | Grant / award · A | +50,000 | — | — | 78,415 |
| Cloonan Michael | President & CEO | Sep 17 | Grant / award · A | +109,025 | — | — | 765,393 |
| Cloonan Michael | President & CEO | Sep 17 | Grant / award · A | +109,025 | — | — | 656,368 |
| Orbimed Advisors Llc | Director | Jul 07 | Disclosed 10b5-1 sale · S | −85,918 | $44.86 | −$3.85M | 2,469,959 |
| Thompson Peter A | Director | Jul 07 | Disclosed 10b5-1 sale · S | −85,918 | $44.86 | −$3.85M | 2,469,959 |
| Fitzpatrick Jennifer | Chief Legal Officer | Jul 06 | Open-market sale · S | −10,250 | $43.60 | −$447K | 0 |
| Fitzpatrick Jennifer | Chief Legal Officer | Jul 06 | Exercise / conversion · M | +10,250 | $6.11 | +$62.6K | 10,250 |
| Orbimed Advisors Llc | Director | Jun 30 | Disclosed 10b5-1 sale · S | −115,844 | $45.50 | −$5.27M | 2,555,877 |
| Thompson Peter A | Director | Jun 30 | Disclosed 10b5-1 sale · S | −115,844 | $45.50 | −$5.27M | 2,555,877 |
| Orbimed Advisors Llc | Director | May 27 | Disclosed 10b5-1 sale · S | −101 | $44.49 | −$4.49K | 2,671,721 |
| Thompson Peter A | Director | May 27 | Disclosed 10b5-1 sale · S | −101 | $44.49 | −$4.49K | 2,671,721 |
| Orbimed Advisors Llc | Director | May 11 | Disclosed 10b5-1 sale · S | −184,639 | $46.22 | −$8.53M | 2,671,822 |
| Thompson Peter A | Director | May 11 | Disclosed 10b5-1 sale · S | −184,639 | $46.22 | −$8.53M | 2,671,822 |
Loading...